LadRx Corporation (LADX)
| Market Cap | 841.66K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.78M |
| Shares Out | 495.09K |
| EPS (ttm) | -5.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Average Volume | 1,294 |
| Open | 1.960 |
| Previous Close | 1.980 |
| Day's Range | 1.700 - 1.960 |
| 52-Week Range | 0.460 - 3.500 |
| Beta | 0.92 |
| RSI | 49.86 |
| Earnings Date | Mar 11, 2025 |
About LadRx
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent which targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorub... [Read more]
Financial Performance
Financial StatementsNews
LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleas...
LadRx Issues 2024 Update to Shareholders
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today is...